Jefferies Reiterates Buy Rating on CRISPR Therapeutics (CRSP) as Overhang Removed
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $159.00 price target on CRISPR Therapeutics (NASDAQ: CRSP), saying an overhang ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
